Organon & Co. Merger Update and Litigation Filing

This Form 8-K filing by Organon & Co. provides an update on the previously disclosed Agreement and Plan of Merger with Sun Pharmaceutical Industries Limited. It addresses litigation filed in the Superior Court of New Jersey, alleging material omissions and misleading statements in the definitive proxy statement related to the merger. The company has voluntarily supplemented the proxy statement to avoid delays and uncertainties, while maintaining that the claims are without merit. The filing also includes supplemental disclosures regarding the merger background, financial analyses by advisors, and unaudited financial projections for Organon. Key financial projections include revenue, Adjusted EBITDA, and Unlevered Free Cash Flow from Q2 2026 through 2030E. The company also states its net debt and estimated Adjusted LTM EBITDA as of March 31, 2026.